What is the pregnancy category of Valsartan/Sacubitril?

Valsartan/Sacubitril, a combination medication used primarily for heart failure, falls under the category of medications that are contraindicated during pregnancy. This classification arises from the substantial evidence indicating that use of the individual components, particularly Valsartan, is associated with risks to fetal development. Angiotensin II receptor blockers, like Valsartan, can cause significant harm to the developing fetus, leading to complications such as renal impairment, skeletal abnormalities, and even fetal death when administered during pregnancy. As a result, healthcare providers strongly advise against the use of this medication in pregnant individuals, highlighting the importance of careful management and consideration of alternative treatments that are safer for both the mother and the fetus.

This understanding aligns with the broader context of safe pharmacological practices during pregnancy, where the potential for harm influenced drug classifications and recommendations. Options implying a lesser level of risk, such as categories A, B, or C, do not apply here due to the clear contraindications associated with Valsartan/Sacubitril in pregnant patients.